Three Seasons Wealth LLC Invests $799,000 in Cencora, Inc. $COR

Posted by Stanley Muller on Jul 16th, 2026

Three Seasons Wealth LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,545 shares of the company’s stock, valued at approximately $799,000.

A number of other hedge funds have also recently modified their holdings of COR. T. Rowe Price Investment Management Inc. raised its stake in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Norges Bank purchased a new stake in shares of Cencora in the 4th quarter valued at approximately $822,506,000. Marshall Wace LLP grew its stake in shares of Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after buying an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Finally, Viking Global Investors LP increased its holdings in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on COR shares. Wells Fargo & Company reduced their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Barclays cut their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. UBS Group upped their price target on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Robert W. Baird lowered their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

Get Our Latest Analysis on Cencora

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.38% of the stock is owned by company insiders.

Cencora Stock Down 1.8%

NYSE:COR opened at $296.71 on Thursday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The stock’s fifty day moving average is $277.99 and its two-hundred day moving average is $317.98. The stock has a market capitalization of $57.73 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

About Cencora

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.